Anti-idiotypic antibody: A new strategy for the development of a growth hormone receptor antagonist. (November 2015)

• Record Type: Journal Article
• Authors: Lan, Hainan; Zheng, Xin; Khan, Muhammad Akram; Li, Steven
• Is Part Of: International journal of biochemistry & cell biology. Volume 68(2015:Nov.)
• Page Start: 101
• Page End: 108
• Publication Date: 2015-11
• Subjects: GH growth hormone -- Mab monoclonal antibody -- PRL prolactin -- GHR growth hormone receptor -- Ab2 anti-idiotypic antibody -- PBS phosphate-buffered saline -- TMB tetramethylbenzidine -- JAK Janus kinase -- STAT signal transducers and activators of transcription -- MAPK mitogen-activated protein kinase; Growth hormone -- Growth hormone receptor -- Anti-idiotypic antibody -- Intracellular signalling -- GHR antagonist; Biochemistry -- Periodicals; Cytology -- Periodicals; Biochemistry -- Periodicals; Cell Biology -- Periodicals; Biochimie -- Périodiques; Cytologie -- Périodiques; Biochimie; Cytologie; Biochemistry; Cytology; Ressource Internet (Descripteur de forme); Périodique électronique (Descripteur de forme); Periodicals; 572.05
• DOI: 10.1016/j.biocel.2015.09.004
• Languages: English
• ISSNs: 1357-2725

Abstract

Highlights: CG-86, an anti-idiotypic antibody, has promise as a novel GHR antagonist. CG-86 may represent have potential advantages over the traditional antagonist. Anti-idiotypic antibody may represent a novel strategy to generate GHR antagonist. Anti-idiotypic strategy may be applied with other cytokines or growth factors. Abstract: In general, traditional growth hormone receptor antagonist can be divided into two major classes: growth hormone (GH) analogues and anti-growth hormone receptor (GHR) antibodies. Herein, we tried to explore a new class of growth hormone receptor (GHR) antagonist that may have potential advantages over the traditional antagonists. For this, we developed a monoclonal anti-idiotypic antibody growth hormone, termed CG-86. A series of experiments were conducted to characterize and evaluate this antibody, and the results from a competitive receptor-binding assay, Enzyme Linked Immunosorbent Assays (ELISA) and epitope mapping demonstrate that CG-86 behaved as a typical Ab2β. Next, we examined its antagonistic activity using in vitro cell models, and the results showed that CG-86 could effectively inhibit growth hormone receptor-mediated signalling and effectively inhibit growth hormone-induced Ba/F3–GHR638 proliferation. In summary, these studies show that an anti-idiotypic antibody (CG-86) has promise as a novel growth hormone receptor antagonist. Furthermore, the current findings also suggest that anti-idiotypic antibody may represent a novel strategy to produce a new class of growth hormone receptor antagonist, and this strategy may be applied with other cytokines or growth factors.